Mustang and the bubble boy bubble
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Upcoming events – pivotal readouts for Intra-Cellular and Myovant
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Medtech
Corporate VC activity in medtech increases – until this year
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
Boston and Coloplast sink on mesh mess
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Company Events
Savara hopes to take a leaf out of Insmed’s book
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
Sillajen and Transgene bid to revive the oncolytic virus craze
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Readouts approach for biggest Huntington’s hopes
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
Interviews
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
Lundbeck needs deals, but what can it afford?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…